Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have received an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $27.40.

A number of equities analysts have issued reports on KMTS shares. The Goldman Sachs Group cut their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 15th. Finally, BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th.

Kestra Medical Technologies Price Performance

KMTS stock opened at $20.69 on Wednesday. The company has a market capitalization of $1.21 billion, a P/E ratio of -5.22 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The business has a 50-day simple moving average of $20.80 and a two-hundred day simple moving average of $22.78.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 45,000 shares of company stock worth $927,150. 3.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $31,000. Russell Investments Group Ltd. raised its holdings in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $72,000. BNP Paribas Financial Markets raised its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.